Molecular Targets 2021: Examining Synthetic Lethality Beyond PARP Inhibitors
Cancer is a very complex disease. Cancer cells often have the ability to rewire some of their functions to survive in harsh...
Tag: PARP inhibitors
Cancer is a very complex disease. Cancer cells often have the ability to rewire some of their functions to survive in harsh...
Epithelial ovarian cancer is by far the most common ovarian cancer subtype, accounting for 90 percent of ovarian cancers. The...
In the final days of 2019, the U.S. Food and Drug Administration (FDA) expanded the use of a previously...
On Friday, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic olaparib (Lynparza) for treating certain...
Several clinical trials are underway in which PARP inhibitors are being tested in breast cancers, mostly triple-negative breast cancers,...
Two studies presented at the AACR Annual Meeting 2017 showed that tumors that have mutations in the proteins isocitrate...
Earlier this week, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic niraparib (Zejula) for the...
Laura Shawver, PhD, is working to change the game for ovarian cancer.
In my first post in this series highlighting some of the studies presented at the AACR Annual Meeting 2015...